Compare AbbVie Inc (ABBV) vs Crocs, Inc. (CROX) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Crocs (CROX) trades at $124.55, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue of $4.04B for 2025 but posted a net loss of $81.20M, with negative profit margins. Recent earnings have consistently beaten expectations, and analyst sentiment remains positive with a 51.35% buy rating and consensus price target of $131.75. News highlights include marketing initiatives like TikTok microdramas and expansion in Asian markets.

The outlook for CROX is mixed: strong brand momentum and earnings beats support upside potential, but profitability concerns and negative net income margins pose risks. Investors should weigh growth initiatives against margin pressures and competitive dynamics in the apparel sector.